A Clinical Perspective of Anti-Fibrotic Therapies for Cardiovascular Disease.
about
The Soft- and Hard-Heartedness of Cardiac Fibroblasts: Mechanotransduction Signaling Pathways in Fibrosis of the Heart.If Channel as an Emerging Therapeutic Target for Cardiovascular Diseases: A Review of Current Evidence and Controversies.Platelet-Rich Plasma Prevents In Vitro Transforming Growth Factor-β1-Induced Fibroblast to Myofibroblast Transition: Involvement of Vascular Endothelial Growth Factor (VEGF)-A/VEGF Receptor-1-Mediated Signaling
P2860
A Clinical Perspective of Anti-Fibrotic Therapies for Cardiovascular Disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 April 2017
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A Clinical Perspective of Anti-Fibrotic Therapies for Cardiovascular Disease.
@en
A Clinical Perspective of Anti-Fibrotic Therapies for Cardiovascular Disease.
@nl
type
label
A Clinical Perspective of Anti-Fibrotic Therapies for Cardiovascular Disease.
@en
A Clinical Perspective of Anti-Fibrotic Therapies for Cardiovascular Disease.
@nl
prefLabel
A Clinical Perspective of Anti-Fibrotic Therapies for Cardiovascular Disease.
@en
A Clinical Perspective of Anti-Fibrotic Therapies for Cardiovascular Disease.
@nl
P2860
P356
P1476
A Clinical Perspective of Anti-Fibrotic Therapies for Cardiovascular Disease
@en
P2093
Anthony M Dart
P2860
P356
10.3389/FPHAR.2017.00186
P577
2017-04-06T00:00:00Z